View More Recent Stories
-
Increasing unusual put option volume: TAL XP CHD MLCO EXC PCG GH RGTI WMB ICE TEM IYR
-
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
-
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
-
TD Cowen Reiterates Buy Rating on Guardant Health (GH)
-
Guardant Health (GH) PT Raised to $55 at BTIG
-
Canaccord Genuity Reiterates Buy Rating on Guardant Health (GH)
-
Guardant Health (GH) and ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
-
Guardant Health (GH) named top pick at UBS
-
Jefferies Reiterates Buy Rating on Guardant Health (GH)
-
Piper Sandler Reiterates Overweight Rating on Guardant Health (GH) After a 'Positive' Survey
-
Guardant Health (GH) Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Guardant Health (GH) PT Raised to $60 at Leerink Partners
-
Guardant Health (GH) Tops Q3 EPS by 29c ; Offers Guidance
-
Guardant Health (GH) Appoints Roberto A. Mignone to its Board
-
Guardant Health (GH) Weakness Said to be Tied to Data From Exact Sciences (EXAS)
-
Midday movers: PDD Holdings, NVIDIA fall; Xpeng gains
-
Guardant Health (GH) enters Open Market Sale Agreement with Jefferies
-
Guardant Health (GH) PT Raised to $42 at TD Cowen
-
Guardant Health (GH) PT Raised to $40 at Jefferies
-
Guardant Health (GH) Tops Q2 EPS by 26c ; Offers Guidance
-
Guardant Health's (GH) FDA-approved Shield Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
-
Guardant Health (GH) PT Raised to $50 at BTIG, 'one of our top two picks in 2024'
-
Exact Sciences (EXAS) Slips 5% After Rival Colorectal Cancer Test Approved by FDA
-
Guardant Health's (GH) Shield Blood Test Approved by FDA as Primary Screening Option, Clearing Path for Medicare Reimbursement
-
Guardant Health (GH) Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360 Test
-
Guardant Health (GH) Appoints Manuel Hidalgo Medina to its Board

